Chemical activators of spermatogenesis associated 31 play a pivotal role in modulating its function through various biochemical pathways, primarily involving the regulation of cyclic AMP (cAMP) levels and the activation of protein kinase A (PKA). Forskolin, by virtue of its ability to directly stimulate adenylate cyclase, elevates cAMP within the cellular environment, which in turn activates PKA. This activation cascade is fundamental to the phosphorylation processes that are essential for the functionality of spermatogenesis associated 31. Similarly, IBMX operates through a non-specific inhibition of phosphodiesterases, culminating in increased cAMP levels and subsequent PKA activation, which can then target spermatogenesis associated 31. The cAMP analog 8-Br-cAMP bypasses upstream signaling and directly engages PKA, leading to a similar activation outcome for spermatogenesis associated 31. Additionally, H-89, though primarily a PKA inhibitor, can paradoxically raise cAMP levels due to feedback loops, thereby indirectly promoting PKA activity and influencing the phosphorylation status of spermatogenesis associated 31.
Continuing along this biochemical thread, chemicals such as LH-21, Zaprinast, Rolipram, Milrinone, Anagrelide, and Cilostamide all contribute to the elevation of cAMP in their unique ways, which in turn fosters PKA activation. LH-21 achieves this through antagonism of cannabinoid receptors, while Zaprinast and Rolipram function as inhibitors of specific phosphodiesterases, leading to the prevention of cAMP breakdown. Milrinone and Anagrelide also inhibit phosphodiesterase 3, thereby enhancing cAMP concentrations, and Cilostamide selectively targets the same enzyme with comparable results. The phosphorylation of spermatogenesis associated 31 by activated PKA ensues, signifying the functional activation of the protein. Sildenafil and Tadalafil, primarily known for their action on phosphodiesterase 5, result in elevated cGMP levels. However, these increases can indirectly affect cAMP levels, which can also result in PKA activation and subsequent phosphorylation of spermatogenesis associated 31, thus contributing to its activation status.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, leading to increased cAMP by preventing its degradation. Elevated cAMP levels can activate PKA, which then could phosphorylate and functionally activate spermatogenesis associated 31 within its role in sperm development. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Br-cAMP is a cell-permeable cAMP analog that directly activates PKA. Through PKA activation, it can phosphorylate substrates involved in spermatogenesis, potentially including spermatogenesis associated 31, thereby functionally activating it. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a phosphodiesterase inhibitor that causes an increase in cAMP levels, leading to PKA activation. PKA can then phosphorylate various proteins involved in spermatogenesis, which may include spermatogenesis associated 31, resulting in its functional activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4, leading to an increase in cAMP and subsequent activation of PKA. PKA can phosphorylate proteins related to spermatogenesis, potentially leading to functional activation of spermatogenesis associated 31. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is a phosphodiesterase 3 inhibitor that increases cAMP levels, promoting PKA activation. Through PKA, it can phosphorylate and activate proteins involved in spermatogenesis, including spermatogenesis associated 31. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits phosphodiesterase 3, increasing cAMP and activating PKA, which may then phosphorylate and functionally activate spermatogenesis associated 31 as part of its role in spermatogenesis. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective inhibitor of phosphodiesterase 3, which enhances cAMP levels, activating PKA. PKA may then target proteins involved in spermatogenesis, including spermatogenesis associated 31, leading to its functional activation. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Tadalafil inhibits phosphodiesterase 5, which primarily affects cGMP but may also lead to increased cAMP levels indirectly. This elevation could activate PKA, which in turn might phosphorylate and activate spermatogenesis associated 31. | ||||||